Open Accessibility Menu

Neurology

About Us

The Department of Neurology at The George Washington University Medical Faculty Associates is a premier program that offers patients high quality, compassionate healthcare for conditions ranging from back pain and sleep disturbances to stroke and the most complex neuromuscular disorders.

Our medical team consists of board-certified neurologists, nurses, EEG technicians, EMG technologists and clinical researchers. Our neurologists are on the forefront of advances in their fields with continuing education and by teaching at The George Washington University School of Medicine & Health Sciences. We offer fellowships in neurophysiology and sleep disorders.

To diagnose neuromuscular disorders we have invested in an advanced electrodiagnostic laboratory that has achieved the highest possible accreditation with exemplary status from the American Association of Neuromuscular & electrodiagnostic Medicine. Ours is the only lab in metropolitan Washington with this designation. It is proof of our commitment to clinical excellence and to providing the highest quality patient care.

We accept most insurance plans and our knowledgeable administrative staff is happy to assist with the approval process and pre-certifications.

Online Forms:

Conveniently Located

Clinical Trials

  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.
  • ARISE: pAdsevonil in drug-ResIStant Epilepsy: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY, PHASE 2
    The primary objectives of this study are to characterize the dose-response relationship with respect to efficacy of PSL administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy and to evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo. The secondary objective is to assess the safety and tolerability of all doses of PSL in relation to placebo.
  • Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial

    The primary objective of this phase 4 study is to evaluate the effectiveness of ESL administered once daily (QD) as the first adjunctive therapy to levetiracetam (LEV) or lamotrigine (LTG) or as a later adjunctive therapy in subjects with partial onset seizures (POS) over a 24-week maintenance period in a real-world setting.

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
  • Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
    To develop a protocol to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.